Investigating how ACSS2 affects colon cancer progression
The role of ACSS2 in colon cancer
This study is looking at how a specific enzyme called ACSS2 affects colon cancer, especially since low levels of it seem to make the cancer worse; by studying samples from people and mice, the researchers hope to find ways to boost ACSS2 to help slow down tumor growth and improve survival for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project ID | NIH-11047569 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of the enzyme ACSS2 in colon cancer. It examines how low levels of ACSS2 are linked to the progression of colorectal cancer and poor patient outcomes. By analyzing both human cancer samples and mouse models, the study aims to uncover the metabolic pathways influenced by ACSS2, particularly in relation to short chain fatty acids produced by gut bacteria. The researchers will explore how increasing ACSS2 expression can potentially limit tumor growth and improve survival rates.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with colorectal cancer, particularly those with low ACSS2 expression.
Not a fit: Patients with other types of cancer or those without colorectal cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that enhance ACSS2 function, potentially improving outcomes for patients with colon cancer.
How similar studies have performed: Previous research has indicated that targeting metabolic pathways in cancer can lead to significant advancements in treatment, suggesting that this approach may hold promise.
Where this research is happening
Charlottesville, United States
- University of Virginia — Charlottesville, United States (Active)
Researchers
- Principal investigator: Wotton, David — University of Virginia
- Study coordinator: Wotton, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.